Screener
AnaptysBio, Inc. ANAB Biopharma Company — Noncash Advance Future Royalties Interest Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept anab:NoncashAdvanceFutureRoyaltiesInterestExpense.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (34,637) | (27,539) |
| Other income (expense), net: | ||
| Interest income | 2,653 | 4,413 |
| Non-cash interest expense for the sale of future royalties | (20,859) | (18,061) |
| Other (expense) income, net | (1) | 1,902 |
| Total other expense, net | (18,207) | (11,746) |
| Loss before income taxes | (52,844) | (39,285) |
| Provision for income taxes | (40) | (44) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — noncash advance future royalties interest expense?
- AnaptysBio, Inc. (ANAB) reported biopharma company — noncash advance future royalties interest expense of $0 in Q1 2026.
- What does biopharma company — noncash advance future royalties interest expense mean?
- This metric tracks the non-cash interest expense associated with financing arrangements involving future royalty streams. It highlights the cost of capital for non-dilutive funding structures used to support clinical development. Investors use this to understand the impact of complex financing agreements on the company's long-term financial obligations.
Ask your AI about AnaptysBio, Inc.'s biopharma company — noncash advance future royalties interest expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude